Efficacy of Sofosbuvir/Daclatasvir in a Single Tablet for Treating Chronic Viral Hepatitis C

Background. Published data regarding the real-life application of combination sofosbuvir/daclatasvir in Algeria are lacking. Therefore, we conducted an observational study to assess efficacy and safety this regimen Algerian patients with chronic hepatitis C. Methods. We carried out a multicentric, observational, open-label generic fixed-dose (FDC) included 100 all genotypes for 12 or 24 weeks treatment without ribavirin. The primary outcome was proportion sustained virologic response (SVR) after cessation. secondary assessed occurrence adverse events. This is registered ClinicalTrials.gov identifier: NCT05138523. Results. full analysis set 99 mean age 51.4 ± 14.4 years sex ratio M/F = 0.86. Our were infected HCV genotype 1b (n 47), 2 17), 1a 3), 2a/2c 2), 3 4 1). A total 27 had missing data. Most naive noncirrhotic 70) took treatment, 19 cirrhosis, which 68.42% 13) classified as Child–Pugh A, 5 treatment-experienced. Both cirrhotic treatment-experienced treatment. Efficacy on 95 patients, results showed that 91 achieved SVR12 rate 95.8% (95% CI: 92–100%). Six events occurred minor manageable. Conclusion. demonstrate single tablets treating ribavirin weeks. promising warrant further trials special populations.